DK3543240T3 - URAT1-inhibitor og anvendelse deraf - Google Patents
URAT1-inhibitor og anvendelse deraf Download PDFInfo
- Publication number
- DK3543240T3 DK3543240T3 DK17872538.8T DK17872538T DK3543240T3 DK 3543240 T3 DK3543240 T3 DK 3543240T3 DK 17872538 T DK17872538 T DK 17872538T DK 3543240 T3 DK3543240 T3 DK 3543240T3
- Authority
- DK
- Denmark
- Prior art keywords
- urat1 inhibitor
- urat1
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611008935 | 2016-11-16 | ||
CN201711115037.9A CN108084186B (zh) | 2016-11-16 | 2017-11-13 | Urat1抑制剂及其应用 |
PCT/CN2017/111013 WO2018090921A1 (zh) | 2016-11-16 | 2017-11-15 | Urat1抑制剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3543240T3 true DK3543240T3 (da) | 2022-10-10 |
Family
ID=62172162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17872538.8T DK3543240T3 (da) | 2016-11-16 | 2017-11-15 | URAT1-inhibitor og anvendelse deraf |
Country Status (18)
Country | Link |
---|---|
US (1) | US10875865B2 (da) |
EP (1) | EP3543240B1 (da) |
JP (1) | JP6925054B2 (da) |
KR (1) | KR102263441B1 (da) |
CN (1) | CN108084186B (da) |
AU (1) | AU2017360465B2 (da) |
CA (1) | CA3043942C (da) |
DK (1) | DK3543240T3 (da) |
ES (1) | ES2923177T3 (da) |
HR (1) | HRP20221151T1 (da) |
HU (1) | HUE059778T2 (da) |
IL (1) | IL266587B2 (da) |
MX (1) | MX2019005565A (da) |
MY (1) | MY197564A (da) |
PL (1) | PL3543240T3 (da) |
PT (1) | PT3543240T (da) |
RS (1) | RS63572B1 (da) |
TW (1) | TWI668213B (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108484600B (zh) * | 2017-05-26 | 2022-12-13 | 江苏新元素医药科技有限公司 | 促尿酸***的urat1抑制剂 |
EP3741759B1 (en) * | 2018-01-19 | 2023-08-23 | Evopoint Biosciences Co., Ltd. | Imidazo[1,2-a]pyrimidine and imidazo[1,2-c]pyrimidine compounds and use thereof in the treatment of hyperuricemia and gout |
CN108623586B (zh) * | 2018-07-16 | 2021-03-16 | 广东工业大学 | 一种咪唑并含氮杂环类化合物的合成方法与应用 |
CN109432079B (zh) * | 2018-09-07 | 2021-06-22 | 江苏康缘药业股份有限公司 | 一种化合物在制备用于痛风的药物中的应用 |
CN111763180B (zh) * | 2019-04-02 | 2023-06-09 | 中国医学科学院药物研究所 | 苯并氮杂环类化合物及其制法和药物用途 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
CN111533718B (zh) * | 2020-05-12 | 2022-05-17 | 浙江海洲制药有限公司 | 一种制备苯溴马隆的方法 |
CN112250688B (zh) * | 2020-10-15 | 2022-11-04 | 天津科技大学 | 一类7-氮杂苯并呋喃衍生物及其在抗肿瘤药物中的应用 |
CN112877295A (zh) * | 2021-02-26 | 2021-06-01 | 华南理工大学 | 一种urat1抑制剂体外活性筛选的细胞模型及其构建方法与筛选方法 |
WO2023221078A1 (en) * | 2022-05-20 | 2023-11-23 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | Solid forms of a compound for treating or preventing hyperuricemia or gout |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117128A (en) * | 1976-08-03 | 1978-09-26 | Smithkline Corporation | Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity |
NZ193926A (en) | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
FR2502622A1 (fr) * | 1981-03-25 | 1982-10-01 | Synthelabo | Derives d'imidazo (1,2-a) pyrimidines, leur preparation et leur application en therapeutique |
US5175184A (en) * | 1982-10-19 | 1992-12-29 | Kotobuki Seiyaku Company Limited | Benzothiophene derivatives and antihyperuricemia thereof |
JPS5973579A (ja) * | 1982-10-19 | 1984-04-25 | Kotobuki Seiyaku Kk | ベンゾフラン又はベンゾチオフェン誘導体,この化合物を有効成分とする尿酸***剤及びその製造方法 |
FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
GB8820231D0 (en) * | 1988-08-25 | 1988-09-28 | Fujisawa Pharmaceutical Co | New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same |
US6166069A (en) * | 1998-05-12 | 2000-12-26 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
AU3791799A (en) * | 1998-05-12 | 1999-11-29 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
CN1533274A (zh) * | 2001-07-20 | 2004-09-29 | �����ɷ� | 苯并呋喃和其在治疗房性纤维颤动中的应用 |
JP2009227599A (ja) * | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
WO2009145456A2 (ko) | 2008-03-31 | 2009-12-03 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 |
US8748435B2 (en) * | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
US20150216867A1 (en) * | 2012-09-25 | 2015-08-06 | Novartis Ag | Compounds for use in gastric complication |
CA2971125A1 (en) * | 2014-12-29 | 2016-07-07 | Nippon Chemiphar Co., Ltd. | Urat1 inhibitor |
CN106008340B (zh) * | 2015-03-24 | 2020-03-17 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
CN106065010B (zh) * | 2015-04-23 | 2019-01-01 | 镇江新元素医药科技有限公司 | 用于治疗或预防高尿酸血症或痛风的化合物 |
CN108727267B (zh) * | 2017-05-26 | 2022-05-13 | 江苏新元素医药科技有限公司 | 一类urat1抑制剂及其应用 |
-
2017
- 2017-11-13 CN CN201711115037.9A patent/CN108084186B/zh active Active
- 2017-11-15 RS RS20220866A patent/RS63572B1/sr unknown
- 2017-11-15 KR KR1020197016720A patent/KR102263441B1/ko active IP Right Grant
- 2017-11-15 US US16/461,298 patent/US10875865B2/en active Active
- 2017-11-15 DK DK17872538.8T patent/DK3543240T3/da active
- 2017-11-15 MY MYPI2019002774A patent/MY197564A/en unknown
- 2017-11-15 TW TW106139575A patent/TWI668213B/zh active
- 2017-11-15 HR HRP20221151TT patent/HRP20221151T1/hr unknown
- 2017-11-15 ES ES17872538T patent/ES2923177T3/es active Active
- 2017-11-15 MX MX2019005565A patent/MX2019005565A/es unknown
- 2017-11-15 AU AU2017360465A patent/AU2017360465B2/en active Active
- 2017-11-15 CA CA3043942A patent/CA3043942C/en active Active
- 2017-11-15 HU HUE17872538A patent/HUE059778T2/hu unknown
- 2017-11-15 PL PL17872538.8T patent/PL3543240T3/pl unknown
- 2017-11-15 EP EP17872538.8A patent/EP3543240B1/en active Active
- 2017-11-15 JP JP2019525953A patent/JP6925054B2/ja active Active
- 2017-11-15 PT PT178725388T patent/PT3543240T/pt unknown
-
2019
- 2019-05-13 IL IL266587A patent/IL266587B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3543240B1 (en) | 2022-07-06 |
MY197564A (en) | 2023-06-23 |
JP6925054B2 (ja) | 2021-08-25 |
IL266587A (en) | 2019-07-31 |
CN108084186A (zh) | 2018-05-29 |
CN108084186B (zh) | 2021-06-25 |
KR20190077083A (ko) | 2019-07-02 |
IL266587B2 (en) | 2023-06-01 |
RS63572B1 (sr) | 2022-10-31 |
CA3043942C (en) | 2021-11-02 |
AU2017360465A1 (en) | 2019-06-06 |
TW201819364A (zh) | 2018-06-01 |
AU2017360465B2 (en) | 2021-02-04 |
HRP20221151T1 (hr) | 2022-11-25 |
ES2923177T3 (es) | 2022-09-26 |
PL3543240T3 (pl) | 2022-10-24 |
US10875865B2 (en) | 2020-12-29 |
TWI668213B (zh) | 2019-08-11 |
KR102263441B1 (ko) | 2021-06-09 |
CA3043942A1 (en) | 2018-05-24 |
EP3543240A1 (en) | 2019-09-25 |
EP3543240A4 (en) | 2020-05-06 |
HUE059778T2 (hu) | 2022-12-28 |
MX2019005565A (es) | 2019-10-30 |
US20200062763A1 (en) | 2020-02-27 |
PT3543240T (pt) | 2022-08-25 |
JP2020503263A (ja) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3227342T4 (da) | Proteinøs heterodimer og anvendelse deraf | |
DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
DK3442972T3 (da) | Bromdomænehæmmere | |
DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3430129T3 (da) | Kolonidannende medium og anvendelse deraf | |
DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
DK3142659T3 (da) | Hiv-1 proteasehæmmere og anvendelser deraf | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
DK3233105T3 (da) | Hidtil ukendt kombination og anvendelse | |
DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
DK3490988T3 (da) | Ny forbindelse og fremgangsmåde | |
DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
DK3337506T3 (da) | Kombinationer og anvendelser deraf |